Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Advanced Cholangiocarcinoma
NCT06178588Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in cholangiocarcinoma (CCA), sponsored by University of Kansas Medical Center. Started Feb 2024; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06178588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178588.